Lenalidomide Teva (Lenalidomide)

Lenalidomide binds to the cereblon protein within the CRL4‑CRBN ubiquitin ligase complex, leading to the degradation of transcription factors Ikaros and Aiolos. This action modulates the immune response, enhances T‑cell and natural‑killer cell activity, and inhibits angiogenesis, contributing to its antineoplastic activity.

The dose of Lenalidomide Teva is individualized by the prescribing physician based on the specific indication, disease stage, renal function, and patient tolerance. Only a qualified healthcare professional should determine the appropriate regimen.

Lenalidomide is classified as potentially teratogenic. It should not be used by pregnant women or women who may become pregnant without effective contraception. Breastfeeding is not recommended while on therapy, and patients should discuss contraceptive options with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lenalidomide belongs to the immunomodulatory drug class, offering a distinct mechanism compared with proteasome inhibitors or monoclonal antibodies. It is often combined with dexamethasone or used as maintenance therapy, providing a complementary approach that can improve progression‑free survival when used according to clinical guidelines.

Store Lenalidomide Teva at temperatures below 25 °C in its original packaging. Protect the product from moisture, excessive heat, and direct sunlight to maintain stability and potency.

Lenalidomide Teva is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed.

Serious risks include venous thromboembolism, severe neutropenia or thrombocytopenia leading to infection or bleeding, secondary primary malignancies, and significant hepatic dysfunction. Patients should be monitored closely for these events throughout therapy.

Lenalidomide Teva is contraindicated in patients with known hypersensitivity to lenalidomide or any component of the formulation. It should also be avoided in individuals who are pregnant, not using effective contraception, or have uncontrolled infections without appropriate medical supervision.